FDA Grants Accelerated Approval to Rybrevant Faspro for Head and Neck Cancer After Platinum and Immunotherapy
A subcutaneous antibody from Johnson & Johnson becomes the first new option in a decade for people whose recurrent head and neck tumours outlasted standard treatment, with a confirmatory study still owed.
Friday, November 6, 2026/2 min read
For people whose head and neck cancer has come back or spread after platinum chemotherapy and immunotherapy, the list of things left to try has been short for a long time. On Thursday the US Food and Drug Administration added one, granting accelerated approval to a subcutaneous antibody that the agency says is the first new treatment for this group in ten years.
The drug is Rybrevant Faspro, the injectable form of amivantamab combined with hyaluronidase, made by Johnson & Johnson's Janssen unit. It was already approved for certain lung cancers, and the FDA announced the new head and neck indication on 5 November.
What did the FDA approve Rybrevant Faspro to treat?
The indication covers adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy and an immunotherapy. It does not extend to HPV-associated oropharyngeal cancers. The approval is accelerated, meaning it rests on how many tumours shrank and for how long rather than on proof that people live longer, and the agency has required confirmatory studies to show whether the response translates into real clinical benefit.
The FDA said the antibody had Breakthrough Therapy designation. Angelo De Claro, director of the agency's Oncology Center of Excellence, called the approval a meaningful step forward for patients.
How well did it work in the trial?
The evidence comes from an open-label, multicentre study of 102 patients. The FDA reports an overall response rate of 42 percent, and 56 percent of those who responded kept their response for six months or longer. The agency contrasts that with roughly 20 percent or less for currently approved therapies. Johnson & Johnson's own summary of the trial, released at the ASCO meeting in May, names it OrigAMI-4 and adds that 15 percent of patients had a complete response, median progression-free survival was 6.8 months and median overall survival was 12.5 months. The median duration of response had not yet been reached.
Those are early numbers from a single-arm study with no comparison group, which is exactly why the approval is conditional.
What are the side effects?
The prescribing information carries warnings for hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, skin reactions, eye toxicity and harm to an unborn baby. In the company's trial data, most treatment-related events were mild or moderate, with low albumin in half of patients, rash in 37 percent and nail-fold inflammation in 34 percent. Administration-related reactions affected 15 percent and none was severe, and 8 percent of patients stopped treatment because of side effects.
What happens next?
Johnson & Johnson now has to complete the confirmatory work, including a phase 3 trial testing the antibody earlier, in first-line disease. Price, launch timing and any European decision were not part of the FDA announcement. For patients, the practical question is whether their oncologist considers them a match, since the label is narrow.
This is reporting, not medical advice. Decisions about cancer treatment, including whether a new drug is appropriate and how to weigh its side effects, belong with an oncologist who knows the patient's history.
Published in The Outspoken Digest
Editorial desk
Outspoken Digest Health DeskMedicine, public health and the research behind the headlines, read carefully.
Newsletter
The Digest, in your inbox
One edition, sent when it is ready. No noise, and your address is never passed on.
Read Next
More Health →
One in Four Adolescents Had No Active Day Last Week, and the Figure Has Not Moved Since 2010, WHO Says
Nov 4, 2026/3 min read
Children's E-Bike Injuries Rose 33 Percent a Quarter at Six US Hospitals, With Twice the Rate of Severe Harm
Nov 3, 2026/2 min read
FDA Proposes More Iodine and Vitamin D in Infant Formula in Its First Nutrient Rewrite Since 1998
Oct 30, 2026/2 min read